Cloudbreak‑B Raises HKD 612M in Ophthalmic Biotech IPO—Cornerstone Backing, R&D Boost Targeted for Visual Therapy Pipeline

IPO Details Purpose of IPOCloudbreak‑B is seeking to raise approximately HKD 612 million by issuing 60.582 million shares at HKD 10.10. Net proceeds (~HKD 522 million) will be allocated to: R&D and clinical development, Expansion of manufacturing...